1 中华医学会神经病学分会，中华医学会神经病学分

会脑血管病学组. 中国急性缺血性脑卒中诊治指南

2014[J]. 中华神经科杂志，2015，48：246-257.

2 重组组织型纤溶酶原激活剂治疗缺血性卒中共识专

家组. 重组组织型纤溶酶原激活剂静脉溶栓治疗缺血

性卒中中国专家共识(2012版)[J]. 中华内科杂志，2012，

51：1006-1010.

3 Liu L，Wang D，Wong KS，et al. Stroke and stroke

care in China：Huge burden，significant workload，

and a national priority[J]. Stroke，2011，42：3651-

3654.

4 Demaerschalk BM，Kleindorfer DO，Adeoye OM，et

al. Scientific rationale for the inclusion and exclusion

criteria for intravenous alteplase in acute ischemic

stroke：A statement for healthcare professionals from

278 Chin J Stroke, Mar 2017, Vol 12, No.3

the American Heart Association/American Stroke

Association[J]. Stroke，2016，47：581-641.

5 Tissue plasminogen activator for acute ischemic

st roke. The National Institute of Neurological

Disorders and Stroke rt-PA Stroke Study Group[J]. N

Engl J Med，1995，333：1581-1587.

6 Hacke W，Donnan G，Fieschi C，et al. Association of

outcome with early stroke treatment：Pooled analysis

of ATLANTIS，ECASS，and NINDS rt-PA Stroke

trials[J]. Lancet，2004，363：768-774.

7 Wa h lg r en N，Ahmed N，Dava l o s A，e t a l .

Thrombolysis with alteplase for acute ischaemic

stroke in the Safe Implementation of Thrombolysis

in Stroke-Monitoring Study (SITS-MOST)：An

observational study[J]. Lancet，2007，369：275-282.

8 Lees KR，Bluhmki E，von Kummer R，et al. Time

to treatment with intravenous alteplase and outcome

in stroke：An updated pooled analysis of ECASS,

ATLANTIS, NINDS and EPITHET trials[J]. Lancet，

2010，375：1695-1703.

9 Liao XL，Wang CX，Wang YL，et al. Implementation

and outcome of thrombolysis with alteplase 3 to

4.5 h after acute stroke in Chinese patients[J]. CNS

Neurosci Ther，2013，19：43-47.

10 Wang Y，Liao X，Zhao X，et al. Using recombinant

tissue plasminogen activator to treat acute ischemic

stroke in China：Analysis of the results from the

Chinese National Stroke Registry (CNSR)[J]. Stroke，

2011，42：1658-1664.

11 Hacke W，Kaste M，Bluhmki E，et al. Thrombolysis

with alteplase 3 to 4. 5 hours after acute ischemic

stroke[J]. N Engl J Med，2008，359：1317-1329.

12 Ahme d N，Wa h lg r e n N，Gr o nd M，e t a l .

Implementation and outcome of thrombolysis with

alteplase 3-4.5 h after an acute stroke：An updated

analysis from SITS-ISTR[J]. Lancet Neurol，2010，9：

866-874.

13 Hacke W. Intravenous thrombolysis with recombinant

tissue plasminogen activator for acute hemispheric

stroke. The European Cooperative Acute Stroke Study

(ECASS)[J]. JAMA，1995，274：1017-1025.

14 Hacke W，Kaste M，Fieschi C，et al. Randomised

double-blind placebo-controlled trial of thrombolytic

therapy with intravenous alteplase in acute ischaemic

stroke (ECASS II)[J]. Lancet，1998，352：1245-1251.

15 the ATLANTIS Study Investigators. Recombinant

tissue-type plasminogen activator (alteplase) for

ischemic stroke 3 to 5 hours after symptom onset：the

ATLANTIS study：A randomized controlled trial[J].

JAMA，1999，282：2019-2026.

16 the Thrombolytic Therapy in Acute Ischemic Stroke

Study Investigators. The rt-PA (alteplase) 0- to 6-hour

acute stroke trial，part a (a0276g) results of a doubleblind，

placebo-controlled，multicenter study[J].

Stroke，2000，31：811-816.

17 the ECASS Investigators. Thrombolysis with alteplase

3 to 4. 5 hours after acute ischemic stroke[J]. N Eng J

Med，2008，359：1317-1329.

18 Anderson CS，Robinson T，Lindley RI，et al. Lowdose

versus standard-dose intravenous alteplase in

acute ischemic stroke[J]. N Eng J Med，2016，24：

2313-2323.

19 Chernyshev OY，Martin-Schild S，Albright KC，et

al. Safety of tPA in stroke mimics and neuroimagingnegative

cerebral ischemia[J]. Neurology，2010，74：

1340-1345.

20 Davis SM，Donnan GA，Parsons MW，et al. Effects

of alteplase beyond 3 h after stroke in the echoplanar

imaging thrombolytic evaluation trial (epithet)：A

placebo-controlled randomised trial[J]. Lancet

Neurol，2008，7：299-309.

21 Garcia-Bermejo P，Calleja AI，Perez-Fernandez

S，et al. Perfusion computed tomography-guided

int ravenous thrombolysis for acut e ischemic

stroke beyond 4.5 hours：A case-control study[J].

Cerebrovascular diseases (Basel，Switzerland)，2012，

34：31-37.

22 Mair G，Wardlaw JM. Imaging of acute stroke

prior to treatment：Current practice and evolving

techniques[J]. Br J Radiol，2014，87：20140216.

23 Schellinger PD，Thomalla G，Fiehler J，et al. MRIbased

and CT-based thrombolytic therapy in acute

stroke within and beyond established time windows：

An analysis of 1210 patients[J]. Stroke，2007，38：

2640-2645.

24 Thomalla G，Schwark C，Sobesky J，et al. Outcome

and symptomat ic bleeding compl icat ions of

intravenous thrombolysis within 6 hours in MRIselected

stroke patients：Comparison of a German

multicenter study with the pooled data of ATLANTIS,

ECASS, and NINDS tPA trials[J]. Stroke，2006，7：

852-858.

25 Amiri H，Bluhmki E，Bendszus M，et al. European

cooperative acute stroke study-4：Extending the time

for thrombolysis in emergency neurological deficits

ECASS-4：Extend[J]. Int J Stroke，2016，11：260-267.

26 Fisher M，Saver JL. Future directions of acute

ischaemic stroke therapy[J]. Lancet Neurol，2015，14：

758-767.

27 Thomalla G，Fiebach JB，Ostergaard L，et al. A

中国卒中杂志 2017年3月 第12卷 第3期 279

multicenter，randomized，double-blind，placebocontrolled

trial to test efficacy and safety of magnetic

resonance imaging-based thrombolysis in wake-up

stroke (wake-up)[J]. Int J Stroke，2014，9：829-836.

28 Wardlaw JM，von Kummer R，Carpenter T，et al.

Protocol for the perfusion and angiography imaging

sub-study of the third international stroke trial (ist-

3) of alteplase treatment within six-hours of acute

ischemic stroke[J]. Int J Stroke，2015，10：956-968.

29 Schul z UG，Fischer U. Poster ior ci rculat ion

cerebrovascular syndromes：Diagnosi s and

management[J]. J Neurol Neurosurg Psychiatry，2016.

30 Nouh A，Remke J，Ruland S. Ischemic posterior

circulation stroke：A review of anatomy，clinical

presentations，diagnosis，and current management[J].

Front Neurol，2014，5：30.

31 Strbian D，Sai ranen T，Silvennoinen H，et al.

Thrombolysis of basilar artery occlusion：Impact of

baseline ischemia and time[J]. Ann Neurol，2013，73：

688-694.

32 Dornak T，Kral M，Hazlinger M，et al. Posterior

vs. Anterior circulation infarction：Demography，

outcomes，and f requency of hemor rhage af ter

thrombolysis[J]. Int J Stroke，2015，10：1224-1228.

33 Schonewille WJ，Wijman CA，Michel P，et al.

Treatment and outcomes of acute basilar artery

occlusion in the basi lar ar ter y internat ional

cooperation study (basics)：A prospective registry

study[J]. Lancet Neurol，2009，8：724-730.

34 Baek JM，Yoon W，Kim SK，et al. Acute basilar

a r t e r y o c c lu s ion：Out come of me cha n ic a l

thrombectomy with solitaire stent within 8 hours of

stroke onset[J]. AJNR Am J Neuroradiol，2014，35：

989-993.

35 Mazya MV LK，Collas D，Rand VM，et al. Iv

thrombolysis in very severe and severe ischemic stroke：

Results from the SITS-ISTR registry[J]. Neurology，

2015，85：2098-2106.

36 Song SS，Latour LL，Ritter CH，et al. A pragmatic

approach using magnetic resonance imaging to

treat ischemic strokes of unknown onset time in a

thrombolytic trial[J]. Stroke，2012，43：2331-2335.

37 Ma ckey J，Kleindorfer D，Sucharew H，et al.

Population-based study of wake-up st rokes[J].

Neurology，2011，76：1662-1667.

38 Nakagawara J，Minematsu K，Okada Y，et al.

Thrombolysis with 0. 6 mg/kg intravenous alteplase

for acute ischemic stroke in routine clinical practice：

The Japan post-Marketing Alteplase Registration

Study (J-MARS)[J]. Stroke，2010，41：1984-1989.

39 Yamaguchi T，Mori E，Minematsu K，et al. Alteplase

at 0.6 mg/kg for acute ischemic stroke within 3 hours

of onset：Japan Alteplase Clinical Trial (J-ACT)[J].

Stroke，2006，37：1810-1815.

40 Dharmasaroja PA，Pat taraarchachai J. Low vs

standard dose of recombinant tissue plasminogen

activator in treating east asian patients with acute

ischemic stroke[J]. Neurol India，2011，59：180-184.

41 MoriharaR. Abe K，Chalmers J. Thrombolysis with

low-dose tissue plasminogen activator 3-4. 5 h after

acute ischemic stroke in five hospital groups in

japan[J]. Transl Stroke Res，2016，2：111-119.

42 国家"九五"攻关课题协作组. 急性脑梗死六小时以内

的静脉溶栓治疗[J]. 中华神经科杂志，2002，35：210-

213.

43 Huang X，Cheripelli BK，Lloyd SM，et al. Alteplase

versus tenecteplase for thrombolysis after ischaemic

stroke (attest)：A phase 2，randomised，open-label，

blinded endpoint study[J]. Lancet Neurol，2015，14：

368-376.

44 Coutts SB，Dubuc V，Mandzia J，et al. Tenecteplasetissue-

type plasminogen activator evaluation for

minor ischemic stroke with proven occlusion[J].

Stroke，2015，46：769-774.

45 Albers GW，von Kummer R，Truelsen T，et al.

Safety and efficacy of desmoteplase given 3-9 h after

ischaemic stroke in patients with occlusion or highgrade

stenosis in major cerebral arteries (dias-3)：A

double-blind，randomised，placebo-controlled phase

3 trial[J]. Lancet Neurol，2015，14：575-584.

46 Ferrari J，Knoflach M，Kiechl S，et al. Early clinical

worsening in patients with TIA or minor stroke：The

Austrian stroke unit registry[J]. Neurology，2010，74：

136-141.

47 Seners P，Turc G，Maier B，et al. Incidence and

predictors of early recanalization after intravenous

thrombolysis：A systemat ic review and metaanalysis[

J]. Stroke，2016，47：2409-2412.

48 Lou M，Safdar A，Mehdiratta M，et al. The HAT

score：A simple grading scale for predict ing

hemorrhage after thrombolysis[J]. Neurology，2008，

71：1417-1423.

49 Cucchiara B，Tanne D，Levine SR，et al. A risk score

to predict intracranial hemorrhage after recombinant

tissue plasminogen activator for acute ischemic

stroke[J]. J Stroke Cerebrovasc Dis，2008，17：331-

333.

50 Menon BK，Saver JL，Prabhakaran S，et al. Risk

score for intracranial hemorrhage in patients with

acute ischemic stroke treated with intravenous tissue280

Chin J Stroke, Mar 2017, Vol 12, No.3

type plasminogen activator[J]. Stroke，2012，43：

2293-2299.

51 Lar r ue V，von Kummer R，del Zoppo G，et al.

Hemor rhagic transformation in acute ischemic

stroke. Potential contributing factors in the european

cooperative acute stroke study[J]. Stroke，1997，28：

957-960.

52 Larrue V，von Kummer RR，Muller A，et al. Risk

factors for severe hemorrhagic transformation in

ischemic stroke patients treated with recombinant

tissue plasminogen activator：A secondary analysis of

the european-australasian acute stroke study (ecass ii)

[J]. Stroke，2001，32：438-441.

53 Mazya M，Egido JA，Ford GA，et al. Predicting the

risk of symptomatic intracerebral hemorrhage in

ischemic stroke treated with intravenous alteplase：

Safe implementation of treatments in stroke (sits)

symptomatic intracerebral hemorrhage risk score[J].

Stroke，2012，43：1524-1531.

54 Xian Y，Liang L，Smith EE，Schwamm LH，et al.

Risks of intracranial hemorrhage among patients with

acute ischemic stroke receiving warfarin and treated

with intravenous tissue plasminogen activator[J].

JAMA，2012，307：2600-2608.

55 Group TNt-PSS. Intracerebral hemorrhage after

intravenous t-PA therapy for ischemic stroke. The

NINDS t-PA stroke study group[J]. Stroke，1997，28：

2109-2118.

56 Giraldo EA，Khalid A，Zand R. Safety of intravenous

thrombolysis within 4. 5 h of symptom onset in

patients with negative post-treatment stroke imaging

for cerebral infarction[J]. Neurocrit Care，2011，15：

76-79.

57 Hacke W KM，Fieschi C，et a l. Int ravenous

thrombolysis with recombinant tissue plasminogen

activator for acute hemispheric stroke. The European

cooperative acute stroke study (ECASS)[J]. J Ame

Med Assoc，1995，274：1017-1025.

58 Lyden PD. S t roke：Haemor rhage r i sk a f ter

thrombolysis：the SEDAN score[J]. Nat Rev Neurol，

2012，8：246-247.

59 Zinkstok SM，Roos YB. Early administration of

aspirin in patients treated with alteplase for acute

ischaemic stroke：A randomised controlled trial[J].

Lancet，2012，380：731-737.

60 Adeoye O，Sucharew H，Khoury J，et al. Combined

approach to lysis utilizing eptifibatide and recombinant

tissue-type plasminogen activator in acute ischemic

stroke-full dose regimen stroke trial[J]. Stroke，2015，

46：2529-2533.

61 Winkler DT，Fluri F，Fuhr P，et al. Thrombolysis in

stroke mimics：Frequency，clinical characteristics，

and outcome[J]. Stroke，2009，40：1522-1525.

62 Forster A，Griebe M，Wolf ME，et al. How to identify

stroke mimics in patients eligible for intravenous

thrombolysis?[J] J Neurol，2012，259：1347-1353.

63 Chang J，Teleb M，Yang JP，et al. A model to prevent

fibrinolysis in patients with stroke mimics[J]. J Stroke

Cerebrovasc dis，2012，21：839-843.

64 Pahs L，Droege C，Kneale H. A novel approach to

the treatment of orolingual angioedema after tissue

plasminogen activator administration[J]. Annals of

emergency medicine，2016，68：345-348.

65 Hurford R，Rezvani S，Kreimei M，et al. Incidence，

predictors and clinical characteristics of orolingual

angio-oedema complicating thrombolysis with tissue

plasminogen activator for ischaemic stroke[J]. J

Neurol Neurosurg Psychiatry，2015，86：520-523.

66 Carandang R，Seshadri S，Beiser A，et al. Trends

in incidence，lifetime risk，severity，and 30-day

mortality of stroke over the past 50 years[J]. JAMA，

2006，296：2939-2946.

67 Wolf PA，D'Agostino RB，O'Neal MA，et al. Secular

t rends in st roke incidence and mor tality. The

framingham study[J]. Stroke，1992，23：1551-1555.

68 Fona row GC，Re eve s MJ，Smi t h EE，e t a l .

Characteristics，performance measures，and inhospital

outcomes of the first one million stroke and

transient ischemic attack admissions in get with the

guidelines-stroke[J]. Circ Cardiovasc Qual Outcomes，

2010，3：291-302.

69 Fonarow GC，Reeves MJ，Zhao X，et al. Age-related

differences in characteristics，performance measures，

treatment trends，and outcomes in patients with

ischemic stroke[J]. Circulation，2010，121：879-891.

70 Bhatnagar P，Sinha D，Parker RA，et al. Intravenous

thrombolysis in acute ischaemic stroke：A systematic

review and meta-analysis to aid decision making in

patients over 80 years of age[J]. J Neurol Neurosurg

Psychiatry，2011，82：712-717.

71 Emberson J，Lees KR，Lyden P，et al. Effect of

treatment delay，age，and stroke severity on the

effects of intravenous thrombolysis with alteplase for

acute ischaemic stroke：A meta-analysis of individual

patient data from randomised trials[J]. Lancet，2014，

384：1929-1935.

72 Mi s h r a NK，Ahmed N，Ander s en G，e t a l .

Thrombolysis in very elderly people：Controlled

comparison of sits international stroke thrombolysis

registry and vir tual international stroke trials

中国卒中杂志 2017年3月 第12卷 第3期 281

archive[J]. BMJ，2010，341：c6046.

73 The benefits and harms of intravenous thrombolysis

with recombinant tissue plasminogen activator within

6 h of acute ischaemic stroke (the third international

stroke trial [ist-3])：A randomised controlled trial[J].

The Lancet，2012，379：2352-2363.

74 Anderson CS，Robinson T，Lindley RI，et al. Lowdose

versus standard-dose intravenous alteplase in

acute ischemic stroke[J]. N Engl J Med，2016，374：

2313-2323.

75 Jauch EC，Saver JL，Adams HP，et al. Guidelines for

the early management of patients with acute ischemic

stroke：A guideline for healthcare professionals from

the American Heart Association/American Stroke

Association[J]. Stroke，2013，44：870-947.

76 Generalized eff icacy of t-PA for acute st roke.

Subgroup analysis of the NINDS t-PA stroke trial[J].

Stroke，1997，28：2119-2125.

77 Seners P，Turc G，Oppenheim C，et al. Incidence，

causes and predictors of neurological deterioration

occurring within 24 h following acute ischaemic

stroke：A systematic review with pathophysiological

implications[J]. J Neurol Neurosurg Psychiatry，2015，

86：87-94.

78 Simonsen CZ，Schmitz ML，Madsen MH，et al. Early

neurological deterioration after thrombolysis：Clinical

and imaging predictors[J]. Int J Stroke，2016，11：776-

782.

79 Smith EE，Fonarow GC，Reeves MJ，et al. Outcomes

in mild or rapidly improving stroke not treated with

intravenous recombinant tissue-type plasminogen

activator：Findings from get with the guidelinesstroke[

J]. Stroke，2011，42：3110-3115.

80 Nedeltchev K，Schwegler B，Haefel i T，et al.

Outcome of stroke with mild or rapidly improving

symptoms[J]. Stroke，2007，38：2531-2535.

81 Smith EE，Abdullah AR，Petkovska I，et al. Poor

outcomes in patients who do not receive intravenous

tissue plasminogen activator because of mild or

improving ischemic stroke[J]. Stroke，2005，36：

2497-2499.

82 Tsivgoulis G，Alexandrov AV，Chang J，et al. Safety

and outcomes of intravenous thrombolysis in stroke

mimics：A 6-year，single-care center study and a

pooled analysis of reported series[J]. Stroke，2011，42：

1771-1774.

83 Levine SR，Khatri P，Broderick JP，et al. Review，

historical context，and clarifications of the ninds rt-

PA stroke trials exclusion criteria：Part 1：Rapidly

improving stroke symptoms[J]. Stroke，2013，44：

2500-2505.

84 Fischer U，Baumgartner A，Arnold M，et al. What is

a minor stroke?[J]. Stroke，2010，41：661-666.

85 Khatri P，Conaway MR，Johnston KC. Ninety-day

outcome rates of a prospective cohort of consecutive

patients with mild ischemic stroke[J]. Stroke，2012，

43：560-562.

86 Rajajee V，Kidwell C，Starkman S，et al. Early MRI

and outcomes of untreated patients with mild or

improving ischemic stroke[J]. Neurology，2006，67：

980-984.

87 Barber PA，Zhang J，Demchuk AM，et al. Why

are stroke patients excluded from tPA therapy? An

analysis of patient eligibility[J]. Neurology，2001，56：

1015-1020.

88 Hsia AW，Sachdev HS，Tomlinson J，et al. Efficacy of

iv tissue plasminogen activator in acute stroke：Does

stroke subtype really matter?[J]. Neurology，2003，61：

71-75.

89 Fuentes B，Martinez-Sanchez P，Alonso de Lecinana

M，et al. Eff icacy of intravenous thrombolysis

according to stroke subtypes：The Madrid stroke

network data[J]. Eur J Neurol，2012，19：1568-1574.

90 Mo l i n a CA，Mont a ne r J，Ar e n i l l a s J F，e t

al. Differential pat tern of tissue plasminogen

activator-induced proximal middle cerebral artery

recanalization among stroke subtypes[J]. Stroke，2004，

35：486-490.

91 Rocha S，Pires A，Gomes J，et al. Intravenous

thrombolysi s is more ef fect ive i n ischemic

cardioembolic strokes than in non-cardioembolic?[J].

Arq Neuropsiquiatr，2011，69：905-909.

92 Hao Z，Liu M，Wang D，et al. Etiologic subtype

predicts outcome in mild stroke：Prospective data

from a hospital stroke registry[J]. BMC Neurol，2013，

13：154.

93 Pan YT，Lee JD，Lin YH，et al. Compar isons

of outcomes in stroke subtypes after intravenous

thrombolysis[J]. Springerplus，2016，5：47.

94 Shobha N，Fang J，Hill MD. Do lacunar strokes

benefit from thrombolysis? Evidence from the registry

of the canadian stroke network[J]. Int J Stroke，2013，

8 Suppl A100：45-49.

95 Dong Y，Cao W，Ren J，et al. Vascular risk factors

in patients with different subtypes of ischemic stroke

may affect their outcome after intravenous tPA[J].

PLoS One，2015，10：e0131487.

96 Leblanc R，Haddad G，Robitaille Y. Cerebral

hemorrhage from amyloid angiopathy and coronary

thrombolysis[J]. Neurosurgery，1992，31：586-590.

282 Chin J Stroke, Mar 2017, Vol 12, No.3

97 Mustanoja S，Meretoja A，Putaala J，et al. Outcome

by stroke etiology in patients receiving thrombolytic

treatment：Descriptive subtype analysis[J]. Stroke，

2011，42：102-106.

98 Chen S，Lu X，Zhang W，et al. Does prior antiplatelet

t reatment increase the r isk of hemor rhagic

transformation and unfavorable outcome on day 90

after intravenous thrombolysis in acute ischemic

stroke patients?[J] J Stroke Cerebrovasc Dis，2016，25：

1366-1370.

99 Me s eg ue r E，Labreuche J，Guidoux C，e t a l.

Outcomes after stroke thrombolysis according to prior

antiplatelet use[J]. Int J Stroke，2015，10：163-169.

100 Rue cke r M，Matos ev ic B，Wi l lei t P，e t a l .

Subtherapeutic warfarin therapy entails an increased

bleeding risk after stroke thrombolysis[J]. Neurology，

2012，79：31-38.

101 Barreto AD，Alexandrov AV，Lyden P，et al. The

argatroban and tissue-type plasminogen activator

stroke study：Final results of a pilot safety study[J].

Stroke，2012，43：770-775.

102 Pol l a c k CV，Rei l ly PA，Ei kelboom J，e t a l .

Idarucizumab for dabigatran reversal[J]. N Engl J

Med，2015，373：511-520.

103 Fr a n k B，Grot t a JC，Al ex a n d r ov AV，e t a l .

Thrombolysis in stroke despite contraindications or

warnings?[J]. Stroke，2013，44：727-733.

104 Meretoja A，Putaala J，Tatlisumak T，et al. Off-label

thrombolysis is not associated with poor outcome in

patients with stroke[J]. Stroke，2010，41：1450-1458.

105 Dong Y，Yang L，Ren J，et al. Intravenous tissue

plasminogen activator can be safely given without

complete blood count results back[J]. PLoS One，2015，

10：e0131234.

106 Selim M，Kumar S，Fink J，et al. Seizure at stroke

onset：Should it be an absolute contraindication

to thrombolysis?[J]. Cerebrovasc Dis (Basel，

Switzerland)，2002，14：54-57.

107 Martin-Schild S，Hallevi H，et al. Aggressive blood

pressure-lowering treatment before intravenous tissue

plasminogen activator therapy in acute ischemic

stroke[J]. Arch Neurol，2008，65：1174-1178.

108 Brott T，Lu M，Kothari R，et al. Hypertension and its

treatment in the NINDS rt-PA stroke trial[J]. Stroke，

1998，29：1504-1509.

109 Zinkstok SM，Vergouwen MD，et al. Safety and

functional outcome of thrombolysis in dissectionrelated

ischemic stroke：A meta-analysis of individual

patient data[J]. Stroke，2011，42：2515-2520.

110 Broderick JP，Palesch YY，Demchuk AM，et al.

Endovascular therapy after intravenous t-PA versus

t-PA alone for stroke[J]. N Engl J Med，2013，368：

893-903.

111 G o y a l M，Demchu k AM，Menon BK，e t a l .

Randomized assessment of rapid endovascular

treatment of ischemic stroke[J]. N Engl J Med，2015，

372：1019-1030.

112 Jovin TG，Chamorro A，Cobo E，et al. Thrombectomy

within 8 hours after symptom onset in ischemic

stroke[J]. N Engl J Med，2015，372：2296-2306.

113 Powers WJ，Derdeyn CP，Biller J，et al. 2015

Amer ican Heart Association/Amer ican Stroke

Association focused update of the 2013 guidelines for

the early management of patients with acute ischemic

stroke regarding endovascular treatment：A guideline

for healthcare professionals from the American Heart

Association/American Stroke Association[J]. Stroke，

2015，46：3020-3035.

114 Sardar P，Chatterjee S，Giri J，et al. Endovascular

therapy for acute ischaemic stroke：A systematic

review and meta-analysis of randomized trials[J]. Eur

Heart J，2015，36：2373-2380.

115 Saver JL，Goyal M，Bonafe A，et al. Stent-retriever

thrombectomy after intravenous t-PA vs . t-PA alone in

stroke[J]. N Engl J Med，2015，372：2285-2295.

116 Smith EE，Schwamm LH. Endovascular clot retrieval

therapy：Implications for the organization of stroke

systems of care in North America[J]. Stroke，2015，46：

1462-1467.

117 Rod r igues FB，Neves JB，Caldei ra D，e t a l .

Endovascular treatment versus medical care alone

for ischaemic stroke：Systematic review and metaanalysis[

J]. BMJ，2016，353：i1754.

118 Sheth KN，Shah N，Morovati T，et al. Intravenous rt-

PA is not associated with increased risk of hemorrhage

in patients with intracranial aneurysms[J]. Neurocrit

Care，2012，17：199-203.

119 Wang HF，Chan CW，Chan HH，et al. Asymptomatic

cerebral aneurysm in stroke patients eligible for

intravenous thrombolytic therapy[J]. Acta Neurol

Taiwan，2013，22：43-48.

120 Haji F，van Adel B，Avery M，et al. Intracranial

aneurysm rupture following intravenous thrombolysis

for stroke[J]. Can J Neurol Sci，2014，41：95-98.

121 Xu M，Yan SQ，Cao J，et al. No hemor rhagic

transformation after intravenous thrombolysis in a

pontine infarction patient with basilar aneurysm[J].

CNS Neurosci Ther，2014，20：473-475.

122 Zaldivar-Jolissaint JF，Messerer M，et al. Rupture of

a concealed aneurysm after intravenous thrombolysis

中国卒中杂志 2017年3月 第12卷 第3期 283

of a thrombus in the parent middle cerebral artery[J].

J Stroke Cerebrovasc Dis，2015，24：e63-e65.

123 Chen F，Yan S，Jin X，et al. Post-thrombolysis

hemor rhage r isk of unr uptured int racranial

aneurysms[J]. Eur Neurol，2015，73：37-43.

124 De Georgia M，Belden J，Pao L，et al. Thrombus

in vertebrobasilar dolichoectatic artery treated with

intravenous urokinase[J]. Cerebrovasc Dis (Basel，

Switzerland)，1999，9：28-33.

125 Sumner CJ，Golden JA，Hemphill JC. Should

thrombolysis be contraindicated in patients with

cerebral arteriovenous malformations?[J]. Crit Care

Med，2002，30：2359-2362.

126 Guillon B，Toulgoat F. Cerebrovascular malformation

revealed during the prethrombolysis workup in acute

ischemic stroke. Impact on therapeutic decision

making[J]. Rev Neurol，2014，170：425-431.

127 Mahaffey KW，Granger CB，Toth CA，et al. Diabetic

retinopathy should not be a contraindication to

thrombolytic therapy for acute myocardial infarction：

Review of ocular hemor rhage incidence and

location in the GUSTO-I trial. Global utilization

of streptokinase and t-PA for occluded coronary

arteries[J]. J Am Coll Cardiol，1997，30：1606-1610.

128 Ebinger M，Winter B，Wendt M，et al. Effect of the

use of ambulance-based thrombolysis on time to

thrombolysis in acute ischemic stroke：A randomized

clinical trial[J]. JAMA，2014，311：1622-1631.

129 Fassbender K，Balucani C，Wal ter S，e t a l .

Streamlining of prehospital stroke management：The

golden hour[J]. Lancet Neurol，2013，12：585-596.

130 Audebert HJ，Saver JL，Starkman S，et al. Prehospital

stroke care：New prospects for treatment and clinical

research[J]. Neurology，2013，81：501-508.

131 Meretoja A，Weir L，Ugalde M，et al. Helsinki model

cut stroke thrombolysis delays to 25 minutes in

melbourne in only 4 months[J]. Neurology，2013，81：

1071-1076.

132 Abboud ME，Band R，Jia J，et al. Recognition of

stroke by EMS is associated with improvement in

emergency department quality measures[J]. Prehosp

Emerg Care，2016，20：729-736.

133 Hsieh MJ，Tang SC，Ko PC，et al. Improved

performance of new prenotification criteria for acute

stroke patients[J]. J Formos Med Assoc，2016，115：

257-262.

134 Walter S，Kostopoulos P，Haass A，et al. Diagnosis

and treatment of patients with stroke in a mobile

st roke unit versus in hospital：A randomised

controlled trial[J]. Lancet Neurol，2012，11：397-404.

135 Zhao J，Liu R. Stroke 1-2-0：A rapid response

programme for stroke in china[J]. Lancet Neurol，

2016.

136 Sauser K，Levine DA，Nickles AV. Hospital variation

in thrombolysis times among patients with acute

ischemic stroke：The contributions of door-to-imaging

time and imaging-to-needle time[J]. JAMA Neurol，

2014，71：1155-1161.

137 Fonarow GC，Zhao X，Smith EE，et al. Doorto-

needle times for tissue plasminogen activator

administ ration and clinical outcomes in acute

i schemic s t roke befor e and af ter a qual i t y

improvement initiative[J]. JAMA，2014，311：1632-

1640.

138 Itrat A，Taqui A，Cerejo R，et al. Telemedicine

in prehospital stroke evaluation and thrombolysis：

Taking stroke treatment to the doorstep[J]. JAMA

Neurol，2016，73：162-168.

139 Kamalian S，Morais LT，Pomerantz SR，et al.

Clot length distribution and predictors in anterior

circulation stroke：Implications for intra-arterial

therapy[J]. Stroke，2013，44：3553-3556.

140 Fransen PS，Berkhemer OA，Lingsma HF，et al. Time

to reperfusion and treatment effect for acute ischemic

stroke：A randomized clinical trial[J]. JAMA Neurol，

2016，73：190-196.

141 Berkhemer OA，Fransen PS，Beumer D，et al. A

randomized trial of intraarterial treatment for acute

ischemic stroke[J]. N Engl J Med，2015，372：11-20.

142 Campbel l BC，Mitchel l PJ，Kleinig TJ，et al.

Endovascular therapy for ischemic stroke with

perfusion-imaging selection[J]. N Engl J Med，2015，

372：1009-1018.

143 Mocco J，Zaidat OO，von Kummer R，e t a l .

Aspiration thrombectomy after intravenous alteplase

versus intravenous alteplase alone[J]. Stroke，2016，47：

2331-2338.

144 Bracard S，Ducrocq X，Mas JL，et al. Mechanical

thrombectomy after intravenous alteplase versus

alteplase alone after stroke (thrace)：A randomised

controlled trial[J]. Lancet Neurol，2016，15：1138-

1147.

145 G oy a l M，Menon BK，van Zwam WH，e t a l .

Endovascular thrombectomy after large-vessel

ischaemic stroke：A meta-analysis of individual

patient data from five randomised trials[J]. Lancet，

2016，387：1723-1731.

146 中华医学会神经病学分会，中华医学会神经病学分会

神经血管介入协作组，急性缺血性脑卒中介入诊疗指

南撰写组. 中国急性缺血性脑卒中早期血管内介入诊

284 Chin J Stroke, Mar 2017, Vol 12, No.3

疗指南[J]. 中华神经科杂志，2015，48：356-361.

147 van Houwelingen RC，Luijckx GJ，Mazuri A，et al.

Safety and outcome of intra-arterial treatment for

basilar artery occlusion[J]. JAMA Neurol，2016，73：

1225-1230.

专家组名单（按姓氏拼音顺序）：

陈会生 沈阳军区总医院

陈康宁 第三军医大学西南医院

程忻 复旦大学附属华山医院

董强 复旦大学附属华山医院

董漪 复旦大学附属华山医院

管阳太 上海交通大学医学院附属仁济医院

郭立 河北医科大学附属第二医院

何俐 四川大学华西医院

李刚 同济大学附属东方医院

李伟荣 太原市中心医院

刘丽萍 首都医科大学附属北京天坛医院

刘新峰 南京军区南京总医院

刘煜敏 武汉大学中南医院

楼敏 浙江大学医学院附属第二医院

罗本燕 浙江大学医学院附属第一医院

牛小媛 山西医科大学第一医院

王伊龙 首都医科大学附属北京天坛医院

王拥军 首都医科大学附属北京天坛医院

徐安定 暨南大学附属第一医院

许予明 郑州大学第一附属医院

杨弋 吉林大学白求恩第一医院

袁军 内蒙古自治区人民医院

张猛 第三军医大学大坪医院

张旭 温州医学院附属第一医院

张玉生 暨南大学附属第一医院

郑华光 首都医科大学附属北京天坛医院